摘要
目的探讨大剂量静脉注射免疫球蛋白治疗危重重症肌无力的临床疗效和安全性。方法按照Ossermann分型,对120例Ⅲ型和Ⅳ型重症肌无力患者采用血浆置换治疗、免疫球蛋白治疗和大剂量糖皮质激素冲击治疗,对上睑肌力、上睑疲劳、眼球水平活动程度、上肢疲劳、下肢疲劳、面肌肌力、吞咽功能及呼吸功能进行绝对评分和相对评分,观察临床疗效和安全性。结果分别对各组患者治疗前后进行绝对评分,差异均具有显著性意义(P<0.05);治疗后血浆置换治疗、免疫球蛋白治疗和大剂量糖皮质激素冲击治疗这三组总有效率与无效率相比差异均有统计学意义(P<0.01),三组之间比较差异无统计学意义(P>0.05);治疗期间未发生严重不良反应。结论应用大剂量静脉注射免疫球蛋白对重症肌无力危重进行治疗,其疗效高,临床疗效好,不良反应较少。
Objective To investigate the efficacy of the clinical trealment and to evaluate the security of crisis myasthenia gravis OVIG） by using high-dose immunoglobulin. Methods According to Ossermann, 120 patients with MG were treated by plasma exchange （A）, high-dose immunoglobulin （t3） and high-dose glucocorticoid （C）. The efficacy of clinical treatment and the security were evaluated by the absolute scores and relative scores on the degree of upper eyelid muscle strength, the degree of upper eyelid fatigue, the degree of eye level activities, the degree of upper limb fatigue, the degree of lower limb fatigue, the degree of facial muscle strength, the swallow function and the breathe function. Results Alter treatment, the absolute scores and relative scores have significant differences on the A, B and C of their own compared to the treatment before （P〈0.05）. There are also have significant differences between the total efficacy and invalid of A, B and C aider treaanent （P〈0.0 1 ）. But there is no significant different on the efficacy of the clinical treatment in A, B and C. Conclusion High-dose immunoglobulin was effective and safe method in treatment of the crisis MG.
出处
《当代医学》
2012年第19期11-13,共3页
Contemporary Medicine
关键词
重症肌无力
免疫球蛋白
绝对评分
相对评分
疗效
Myasthenia gravis
Immunoglobulin
Absolute scores
Relative scores
Therapeutic efficacy
